Rai Staging System for Chronic Lymphocytic Leukemia (CLL)
Stages chronic lymphocytic leukemia, similar to Binet Staging System.
Use in patients with lymphocytosis (absolute lymphocytes ≥15,000/mm³ in blood and ≥40% lymphocytes in marrow). Lymph nodes, spleen, and liver are considered enlarged if palpable on exam.
Advice
Stage alone should not dictate treatment; consider symptoms and patient comorbidities. Use clinical judgment and specialist recommendations to guide management decisions.
Management
- Low risk (stage 0):
- Monitor with a "watch and wait" approach unless symptoms or disease progression occurs.
- Focus on regular follow-ups and patient education.
- Intermediate risk (stages I–II):
- A “watch and wait” approach may be appropriate for asymptomatic individuals.
- Assess for additional prognostic factors and signs of disease progression.
- Consider initiating treatment if symptomatic or if there is rapid progression.
- High risk (stages III–IV):
- Initiate appropriate therapy based on patient and tumor characteristics, as well as goals of care.
- Evaluate for clinical trials, especially in cases of high-risk genetic mutations.
- For early-stage, asymptomatic CLL (stages 0–II), consider the IPS-E to predict the time to first treatment, helping to reaffirm treatment decisions and guide monitoring frequency.